A phase 1/2 safety and efficacy study of TAK-754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials
TAK-754基因疗法的1/2期安全性和有效性研究:在A型血友病临床试验中实现持久性VIII因子表达的挑战
期刊:Haemophilia
影响因子:3
doi:10.1111/hae.15121
Chapin, John; Álvarez Román, Maria Teresa; Ayash-Rashkovsky, Mila; Diogo, Dorothee; Kenniston, Jon; Lopez-Jaime, Francisco-Jose; Maggiore, Caterina; Mingot-Castellano, María-Eva; Rajavel, Kavitha; Rauch, Antoine; Susen, Sophie; von Grotthuss, Marcin; Wagoner, Matt; Wang, Qin